12:00 AM
Feb 11, 2013
 |  BioCentury  |  Emerging Company Profile

GeneCentric: Cancer sign-off

GeneCentric is developing cancer diagnostics based on gene signatures

GeneCentric Diagnostics Inc. was founded to translate gene sequences into out-licensable assets for partners to market as laboratory-developed tests. The first product based on a GeneCentric assay - a test to help subtype non-small cell lung cancer and guide therapy - was launched by Laboratory Corp. of America Holdings last month.

President and CEO Myla Lai-Goldman said GeneCentric's first programs are based on two genetic signatures identified by University of North Carolina researchers and company co-founders David Neil Hayes and Charles Perou. GeneCentric exclusively licensed the IP last year.

The company's first product is a 54-gene assay designed to distinguish between squamous and adenocarcinoma subtypes of non-small cell lung cancer (NSCLC).

Lai-Goldman said the product is meant for use as an adjunct to histopathological review - the gold standard - to help define the subtype of a lung tumor biopsy and to guide use of drugs, such as Alimta pemetrexed and Avastin bevacizumab.

Eli Lilly and...

Read the full 789 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >